Drug Profile
KT 009
Alternative Names: KT009; Recombinant growth factor - Kunovus TechnologiesLatest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Kunovus Technologies
- Class Growth factors
- Mechanism of Action Protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Intervertebral disc degeneration
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Intervertebral-disc-degeneration in Australia (Injection)
- 08 Nov 2018 Medigard has patent protection for KT 009 in USA
- 30 Oct 2018 KT 009 is available for licensing as of 30 Oct 2018. http://www.medigard.com.au/index2